NASDAQ:LABP

Landos Biopharma (LABP) Stock Forecast, Price & News

$2.60

-0.16 (-5.80%)

(As of 10:55 AM ET)

Compare

Today's Range: $2.50
▼
$2.85
50-Day Range: $2.60
▼
$28.90
52-Week Range: $2.11
▼
$13.70

Volume: 31,207 shs
Average Volume: 29,795 shs
Market Capitalization: $8.11 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $30.00

Landos Biopharma MarketRank™ Forecast

Analyst Rating: Hold
1.67 Rating Score
Upside/Downside: 990.9% Upside
$30.00 Price Target
Short Interest: Healthy
0.24% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.34
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($4.30) to ($4.15) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

2.8

Analyst's Opinion

Consensus Rating
Landos Biopharma has received a consensus rating of Hold. The company's average rating score is 1.67, and is based on no buy ratings, 2 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $30.00, Landos Biopharma has a forecasted upside of 990.9% from its current price of $2.75.
Amount of Analyst Coverage
Landos Biopharma has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.24% of the float of Landos Biopharma has been sold short.
Short Interest Ratio / Days to Cover
Landos Biopharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Landos Biopharma has recently increased by 1.88%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Landos Biopharma does not currently pay a dividend.
Dividend Growth
Landos Biopharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LABP.

2.4

News and Social Media Coverage

News Sentiment
Landos Biopharma has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Landos Biopharma this week, compared to 0 articles on an average week.
MarketBeat Follows
1 people have added Landos Biopharma to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Landos Biopharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
13.50% of the stock of Landos Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
59.31% of the stock of Landos Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Landos Biopharma are expected to grow in the coming year, from ($4.30) to ($4.15) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Landos Biopharma is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Landos Biopharma is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Landos Biopharma has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Landos Biopharma (NASDAQ:LABP) Stock

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA). Its preclinical candidates in development include LABP-66 is an oral and small molecule NOD-like pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA; LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; and LABP-111, an oral and small molecule LANCL2 pathway agonist for the treatment of nonalcoholic steatohepatitis and type 1 diabetes. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.

Receive LABP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Landos Biopharma and its competitors with MarketBeat's FREE daily newsletter.

LABP Stock News Headlines

May 31, 2023 | finance.yahoo.com

Landos Biopharma to Present at the 2023 Jefferies Healthcare Conference

May 26, 2023 | finanznachrichten.de

Landos Biopharma, Inc.: Landos Biopharma Announces 1-for-10 Reverse Stock Split

June 1, 2023 | Edge On The Street (Ad)

AI is Unstoppable. Now Is The Time!

AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.

May 25, 2023 | msn.com

Landos Biopharma implements 1-for-10 reverse stock split to regain compliance with Nasdaq requirements

May 25, 2023 | finance.yahoo.com

Landos Biopharma Announces 1-for-10 Reverse Stock Split

May 16, 2023 | seekingalpha.com

LABP Landos Biopharma, Inc.

May 14, 2023 | americanbankingnews.com

Landos Biopharma (NASDAQ:LABP) Announces Quarterly Earnings Results

May 12, 2023 | finanznachrichten.de

Landos Biopharma, Inc.: Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results

June 1, 2023 | Edge On The Street (Ad)

AI is Unstoppable. Now Is The Time!

AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.

May 12, 2023 | msn.com

Recap: Landos Biopharma Q1 Earnings

May 12, 2023 | finance.yahoo.com

UPDATE -- Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results

May 12, 2023 | finance.yahoo.com

Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results

May 9, 2023 | americanbankingnews.com

Landos Biopharma (LABP) Scheduled to Post Quarterly Earnings on Wednesday

May 9, 2023 | americanbankingnews.com

Landos Biopharma (LABP) to Release Quarterly Earnings on Wednesday

May 1, 2023 | americanbankingnews.com

Landos Biopharma, Inc. (NASDAQ:LABP) Short Interest Down 10.8% in April

March 28, 2023 | markets.businessinsider.com

JonesTrading Reaffirms Their Hold Rating on Landos Biopharma (LABP)

March 1, 2023 | seekingalpha.com

Theravance Biopharma Q4 results mixed, co to reduce headcount by about 17%

February 28, 2023 | technews.tmcnet.com

Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos' Founder

February 28, 2023 | finance.yahoo.com

Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos’ Founder

January 11, 2023 | finance.yahoo.com

Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohn’s and Colitis Organization

January 5, 2023 | msn.com

Landos Biopharma announces $16.7M private placement

January 5, 2023 | finance.yahoo.com

Landos Biopharma Announces $16.7 Million Private Placement Financing

January 5, 2023 | finance.yahoo.com

Landos Biopharma Provides Comprehensive Update on Clinical Development Plans

November 10, 2022 | finanznachrichten.de

Landos Biopharma, Inc.: Landos Biopharma Reports Third Quarter 2022 Results and Provides Business Update

November 10, 2022 | finance.yahoo.com

Landos Biopharma Reports Third Quarter 2022 Results and Provides Business Update

October 15, 2022 | yahoo.com

TransCelerate BioPharma Appoints Janice Chang as New CEO

October 15, 2022 | finance.yahoo.com

We're A Little Worried About Landos Biopharma's (NASDAQ:LABP) Cash Burn Rate

See More Headlines

LABP Price History

30 days | 90 days | 365 days | Advanced Chart

LABP Company Calendar

Last Earnings: 5/12/2023
Today: 6/01/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:LABP
CUSIP: N/A
CIK: 1785345
Web: landosbiopharma.com
Phone: 540-218-2232
Fax: N/A
Employees: 46
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $30.00
High Stock Price Forecast: $30.00
Low Stock Price Forecast: $30.00
Forecasted Upside/Downside: +990.9%
Consensus Rating: Hold
Rating Score (0-4): 1.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($7.00)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-39,280,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -67.03%
Return on Assets: -59.71%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.30
Quick Ratio: 12.30

Sales & Book Value

Annual Sales: $18 million
Price / Sales: 0.48
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $15.09 per share
Price / Book: 0.18

Miscellaneous

Outstanding Shares: 3,120,000
Free Float: 2,696,000
Market Cap: $8.58 million
Optionable: Not Optionable
Beta: -1.15

Key Executives

Mr. Timothy M. Mayleben M.B.A. (Age 61)
Principal Financial Officer & Director
Comp: $513.2k

Dr. Josep Bassaganya-Riera DVM (Age 47)
Ph.D., Advisor
Comp: $1.79M

Mr. Gregory Oakes (Age 54)
Pres, CEO & Director

Mr. Patrick Truesdell (Age 41)
Principal Accounting Officer

Dr. Fabio Cataldi M.D.
Chief Medical Officer

Key Competitors

View All Competitors

Insiders

Rtw Investments, Lp
Sold 30,000 shares
Total: $207,000.00 ($6.90/share)

View All Insider Transactions

LABP Stock - Frequently Asked Questions

Should I buy or sell Landos Biopharma stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Landos Biopharma in the last year. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" LABP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LABP, but not buy additional shares or sell existing shares.
View LABP analyst ratings or view top-rated stocks.
What is Landos Biopharma's stock price forecast for 2023?: 3 analysts have issued 12 month price objectives for Landos Biopharma's shares. Their LABP share price forecasts range from $30.00 to $30.00. On average, they expect the company's share price to reach $30.00 in the next year. This suggests a possible upside of 990.9% from the stock's current price.
View analysts price targets for LABP or view top-rated stocks among Wall Street analysts.
How have LABP shares performed in 2023?: Landos Biopharma's stock was trading at $5.0010 at the beginning of 2023. Since then, LABP stock has decreased by 45.0% and is now trading at $2.75.
View the best growth stocks for 2023 here.
When is Landos Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our LABP earnings forecast.
How were Landos Biopharma's earnings last quarter?: Landos Biopharma, Inc. (NASDAQ:LABP) issued its quarterly earnings data on Friday, May, 12th. The company reported ($0.90) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.10.
When did Landos Biopharma's stock split?: Landos Biopharma's stock reverse split on the morning of Friday, May 26th 2023. The 1-10 reverse split was announced on Friday, May 26th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Landos Biopharma IPO?: (LABP) raised $101 million in an IPO on Thursday, February 4th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and SVB Leerink served as the underwriters for the IPO and Raymond James was co-manager.
What is Landos Biopharma's stock symbol?: Landos Biopharma trades on the NASDAQ under the ticker symbol "LABP."
How do I buy shares of Landos Biopharma?: Shares of LABP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Landos Biopharma's stock price today?: One share of LABP stock can currently be purchased for approximately $2.75.
How much money does Landos Biopharma make?: Landos Biopharma (NASDAQ:LABP) has a market capitalization of $8.58 million and generates $18 million in revenue each year. The company earns $-39,280,000.00 in net income (profit) each year or ($7.00) on an earnings per share basis.
How can I contact Landos Biopharma?: Landos Biopharma's mailing address is 1800 KRAFT DRIVE SUITE 216, BLACKSBURG VA, 24060. The official website for the company is landosbiopharma.com. The company can be reached via phone at 540-218-2232 or via email at thoffmann@troutgroup.com.

This page (NASDAQ:LABP) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial